^
No biomarker
Oropharyngeal Cancer
TPF
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
cisplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
afatinib
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
capecitabine
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
methotrexate
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
docetaxel
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
carboplatin
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
cetuximab
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
carboplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
cisplatin + docetaxel
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
nivolumab
Sensitive: A2 - Guideline
PD-L1 expression
Oropharyngeal Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
cisplatin + paclitaxel + 5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
5-fluorouracil + hydroxyurea
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
carboplatin + 5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Oropharyngeal Cancer
cisplatin
Sensitive: A2 - Guideline
ITGAE overexpression
Oropharyngeal Cancer
cetuximab
Sensitive: C3 – Early Trials